


PHARMACEUTICAL 2021

CymaBay Therapeutics Inc. Rank 161 of 409







CymaBay Therapeutics Inc. Rank 161 of 409

The relative strengths and weaknesses of CymaBay Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CymaBay Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 254% points. The greatest weakness of CymaBay Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is -61%, being 294% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	151,585
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,857
Liabilities, Non-Current	1,262
Other Assets	479
Other Compr. Net Income	-72
Other Expenses	-705
Other Liabilities	0
Other Net Income	1,616
Property and Equipment	1,761
Research and Development	35,882
Revenues	0
Selling, General and Administrative Expense	17,425

Output Variable	Value in 1000 USD
Assets	153,825
Liabilities	11,119
Expenses	52,602
Stockholders Equity	142,706
Net Income	-50,986
Comprehensive Net Income	-51,022
Economic Capital Ratio	-61%

